Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center, discusses the current standard of treatment for patients with advanced endometrial cancer as well as the role novel therapies, such as targeted therapies and immunotherapy, play in the treatment of the disease.
Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center, discusses the current standard of treatment for patients with advanced endometrial cancer as well as the role novel therapies, such as targeted therapies and immunotherapy, play in the treatment of the disease.
Transcript
What is the current standard of treatment for patients with advanced endometrial cancer?
Our current standard of care treatment for advanced endometrial cancer would usually be surgery first, if it looks doable by their imaging, meaning it’s confined to the abdomen and pelvis, there’s not distant disease like in the lungs or someplace where we don’t think we can resect it. Then, usually that’s followed by chemotherapy. The 2 drugs that have the greatest efficacy for endometrial cancer right now is paclitaxel and carboplatin, and usually that’s 6 cycles of both treatments. Then, plus or minus radiation, depending on the treating gynecologic oncologist’s preference and sort of risk factors and things in where the cancer was and wasn’t during the surgery.
Do targeted therapies or immunotherapy play a role in the treatment of endometrial cancer? Are there any identified biomarkers to predict response to these therapies?
So, right now there haven’t been any FDA approved treatments for endometrial cancer, which would include targeted therapies, actually since hormonal therapy. So, we really desperately need more research on targeted therapies for endometrial cancer for sure. We are looking at many things, including mTOR inhibitors. We’re looking at antiangiogenic agents.
I think the things we’re most excited about is PD-1 inhibitor therapy with mismatched repair deficient tumors looking like a good biomarker for immunotherapy for endometrial cancer. Also, endometrial cancers have a fair amount of tumors that are mismatched repair deficient. So, I think right now that’s our most exciting biomarker and treatment, and there is FDA approval for PD-1 inhibitors in patients across cancers that have mismatched repair deficient tumors.
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
SABCS 2023 Sessions Touch on "Every Aspect of Breast Cancer"
December 4th 2023The 46th annual San Antonio Breast Cancer Symposium will take place December 5-9, with new and experienced attendees able to choose and learn from a schedule overflowing with the latest developments in breast cancer science and research.
Read More
Gaps in Access to Cancer Care Resources May Contribute to Racial, Ethnic Disparities
December 1st 2023Researchers found that core oncology services were less likely to be available at hospitals serving racial and ethnic minority groups compared with other hospitals in the United States.
Read More
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More